First look: testing new drug safety in kidney patients
NCT ID NCT07348237
Summary
This early-stage study aims to understand how a new drug called MK-2828 behaves in the bodies of people with kidney disease. Researchers will give a single dose to 24 participants, including people with severe kidney impairment and those on dialysis, and compare their drug levels to healthy volunteers. The main goal is to see if kidney problems change how the drug is processed, which is crucial for determining safe future dosing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Floridian Clinical Research
RECRUITINGMiami Lakes, Florida, 33016, United States
Conditions
Explore the condition pages connected to this study.